Merck raised its full-year 2026 adjusted earnings and sales guidance on October 29 as it reported third-quarter results. The updated Merck outlook includes a one-time charge related to a global licensing agreement.

Merck outlook for 2026

The pharmaceutical company now expects adjusted earnings of $2.77 to $2.82 per share, compared with its previous forecast of $2.66 to $2.76 per share.

Merck also projects sales of $66.8 billion to $67.3 billion, up from its earlier range of $66.3 billion to $67.3 billion. The revision raises the lower end of the sales forecast while leaving the upper end unchanged.

The earnings guidance includes a one-time charge of $0.12 per share related to a global license agreement with SciBrunch Therapeutics Co., Ltd. The figures are forecasts, not completed full-year results.

Shares and earnings call

Merck shares traded at $144.01 in premarket trading on October 29, up $2.97, or 2.11%.

In its conference call announcement, Merck scheduled a discussion of its third-quarter performance with institutional investors and analysts for 9:00 a.m. ET on October 29. The company said a webcast replay and supplementary financial materials would be available.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.